Skip to cookie consent Skip to main content

Mass General Brigham Ventures

Mass General Brigham Ventures is an early-stage venture capital firm that advances new life science technologies emerging from Mass General Brigham’s extensive research network. We invest in bringing bench-to-bedside innovations to market, making a positive impact on the quality of health care worldwide.

Technical and Financial graph on abstract technology background

Investing in bold, transformative ideas 

Mass General Brigham Ventures invests exclusively in health care sector companies based on intellectual property created within our own research community.   

We find and invest in new ventures based on novel life science technologies emerging from Mass General Brigham’s world-class research community, the largest medical research engine in the United States. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.

When we invest, we support our portfolio companies through their entire financing lifecycles. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.

Mass General Brigham’s academic hospitals and Harvard Medical School faculty and more than 6,000 investigators serve as primary sources of intellectual capital assets for venture investments with more than $2 billion in federal funding annually. Our teams of investigators bring forth new and effective ways to diagnose, prevent, and cure disease every day. We work side-by-side with our scientific founders to build companies around innovative science and to provide the early-stage care and feeding necessary to thrive. Today, we manage three funds with more than $450 million in capital from both internal and external sources.

Mass General Brigham Ventures is helping advance the MGB mission by investing in bold, transformative ideas that leverage our strength and depth in world-class scientific research. MGB Ventures plays a key part in moving these discoveries into clinical care by funding nascent technologies that have the potential to revolutionize healthcare and provide better treatment to patients.

Anne Klibanski, MD
President & CEO
Mass General Brigham

A unique investment platform

Our unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. With visibility and access to Mass General Brigham's vast intellectual property estate, we have a privileged position to originate new ventures that advance novel medicines.

Legacy of innovation

Mass General Brigham hospitals share a legacy of innovation that includes 18 Nobel laureates and the development of therapies that have redefined the contemporary standard of care. The scope of the research enterprise is rooted in leadership and innovation spanning more than 150 years, as Mass General Brigham hospitals have been home to many of the world’s most notable medical advances.  

Mass General Brigham is a widely acknowledged academic leader in scientific and clinical research. Our hospitals boast a history of medical firsts, including the use of TNF fusion protein for the treatment of rheumatoid arthritis (Enbrel®); elucidation of PD-1 receptor biology that spawned the field of immuno-oncology therapy; the discovery of CRISPR gene-editing technology; and the targeting of EGFR gene mutations that enable high-efficacy personalized lung cancer therapy.  

Below is just a further sampling of the hundreds of products, discoveries, and best practices originating at Mass General Brigham hospitals, where a culture of innovation is ingrained in their missions: 

  • The world’s first public administration of the surgical use of anesthesia took place in Mass General Hospital’s Ether Dome on October 16, 1846  
  • The first X-ray machine for medical use in the U.S. was made at Mass General in 1896  
  • The world’s first organ transplant was performed in 1954 by Nobel laureate Joseph Murray, MD, at Peter Bent Brigham Hospital, one of three hospitals merged to form Brigham and Women’s Hospital  
  • McLean Hospital scientists were the first to find cement-like protein polymers in the brain fibers of patients with Alzheimer’s disease  
  • Brigham and Women’s Hospital investigators developed C-reactive protein (CRP), a widely ordered biomarker diagnostic test for cardiac risk    
  • A team of investigators led by Mass General neurologist Rudolph Tanzi, MD, discovered four new Alzheimer’s disease gene candidates    
  • Investigators at McLean Hospital’s Brain Imaging Center reported immediate and substantial mood improvement using low-field magnetic stimulation (LFMS)—a treatment unlike any other—for patients suffering from depression and bipolar disorder ​ 

Our portfolio

We support companies that are working to solve important health care needs via cutting-edge breakthroughs in medicine and science. Since inception in 2008, we have invested in 54 companies, realized 15 successful exits, and produced top venture returns.